Toll Free: 1-888-928-9744
Published: Feb, 2014 | Pages:
48 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Synta Pharmaceuticals Corp. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Synta Pharmaceuticals Corp. - Product Pipeline Review - 2014', provides an overview of the Synta Pharmaceuticals Corp.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Synta Pharmaceuticals Corp.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Synta Pharmaceuticals Corp. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Synta Pharmaceuticals Corp.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Synta Pharmaceuticals Corp.'s pipeline products Reasons to buy - Evaluate Synta Pharmaceuticals Corp.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Synta Pharmaceuticals Corp. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Synta Pharmaceuticals Corp.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Synta Pharmaceuticals Corp. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Synta Pharmaceuticals Corp. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Synta Pharmaceuticals Corp. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Synta Pharmaceuticals Corp. Snapshot 5 Synta Pharmaceuticals Corp. Overview 5 Key Information 5 Key Facts 5 Synta Pharmaceuticals Corp. - Research and Development Overview 6 Key Therapeutic Areas 6 Synta Pharmaceuticals Corp. - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 Synta Pharmaceuticals Corp. - Pipeline Products Glance 12 Synta Pharmaceuticals Corp. - Late Stage Pipeline Products 12 Phase III Products/Combination Treatment Modalities 12 Synta Pharmaceuticals Corp. - Clinical Stage Pipeline Products 13 Phase II Products/Combination Treatment Modalities 13 Phase I Products/Combination Treatment Modalities 14 Synta Pharmaceuticals Corp. - Early Stage Pipeline Products 15 Preclinical Products/Combination Treatment Modalities 15 Synta Pharmaceuticals Corp. - Drug Profiles 16 ganetespib 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 elesclomol 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 CRACM Channel Inhibitors 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 HSP90i 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Small Molecule to Inhibit IL 12/IL 23 For Autoimmune Disorders And Inflammation 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 STA-2842 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 STA-9584 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Synta Pharmaceuticals Corp. - Pipeline Analysis 28 Synta Pharmaceuticals Corp. - Pipeline Products by Target 28 Synta Pharmaceuticals Corp. - Pipeline Products by Route of Administration 29 Synta Pharmaceuticals Corp. - Pipeline Products by Molecule Type 30 Synta Pharmaceuticals Corp. - Pipeline Products by Mechanism of Action 31 Synta Pharmaceuticals Corp. - Recent Pipeline Updates 32 Synta Pharmaceuticals Corp. - Dormant Projects 43 Synta Pharmaceuticals Corp. - Discontinued Pipeline Products 44 Discontinued Pipeline Product Profiles 44 apilimod mesylate 44 Synta Pharmaceuticals Corp. - Company Statement 45 Synta Pharmaceuticals Corp. - Locations And Subsidiaries 46 Head Office 46 Appendix 47 Methodology 47 Coverage 47 Secondary Research 47 Primary Research 47 Expert Panel Validation 47 Contact Us 48 Disclaimer 48
List of Tables Synta Pharmaceuticals Corp., Key Information 5 Synta Pharmaceuticals Corp., Key Facts 5 Synta Pharmaceuticals Corp. - Pipeline by Indication, 2014 8 Synta Pharmaceuticals Corp. - Pipeline by Stage of Development, 2014 10 Synta Pharmaceuticals Corp. - Monotherapy Products in Pipeline, 2014 11 Synta Pharmaceuticals Corp. - Phase III, 2014 12 Synta Pharmaceuticals Corp. - Phase II, 2014 13 Synta Pharmaceuticals Corp. - Phase I, 2014 14 Synta Pharmaceuticals Corp. - Preclinical, 2014 15 Synta Pharmaceuticals Corp. - Pipeline by Target, 2014 28 Synta Pharmaceuticals Corp. - Pipeline by Route of Administration, 2014 29 Synta Pharmaceuticals Corp. - Pipeline by Molecule Type, 2014 30 Synta Pharmaceuticals Corp. - Pipeline Products by Mechanism of Action, 2014 31 Synta Pharmaceuticals Corp. - Recent Pipeline Updates, 2014 32 Synta Pharmaceuticals Corp. - Dormant Developmental Projects,2014 43 Synta Pharmaceuticals Corp. - Discontinued Pipeline Products, 2014 44
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.